|
1
|
Huang C, Wang Y, Li X, Ren L, Zhao J, Hu
Y, Zhang L, Fan G, Xu J, Gu X, et al: Clinical features of patients
infected with 2019 novel coronavirus in Wuhan, China. Lancet.
395:497–506. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Scott L, Hsiao NY, Moyo S, Singh L,
Tegally H, Dor G, Maes P, Pybus OG, Kraemer MUG, Semenova E, et al:
Track omicron's spread with molecular data. Science. 374:1454–1455.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Dyer O: Covid-19: South Africa's surge in
cases deepens alarm over omicron variant. BMJ. 375:n30132021.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Callaway E and Ledford H: How bad is
Omicron? What scientists know so far. Nature. 600:197–199. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Giovanetti M, Benedetti F, Campisi G,
Ciccozzi A, Fabris S, Ceccarelli G, Tambone V, Caruso A, Angeletti
S, Zella D and Ciccozzi M: Evolution patterns of SARS-CoV-2:
Snapshot on its genome variants. Biochem Biophys Res Commun.
538:88–91. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lan J, Ge J, Yu J, Shan S, Zhou H, Fan S,
Zhang Q, Shi X, Wang Q, Zhang L and Wang X: Structure of the
SARS-CoV-2 spike receptor-binding domain bound to the ACE2
receptor. Nature. 581:215–220. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Chen Y, Liu Q and Guo D: Emerging
coronaviruses: Genome structure, replication, and pathogenesis. J
Med Virol. 92:418–423. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ke Z, Oton J, Qu K, Cortese M, Zila V,
McKeane L, Nakane T, Zivanov J, Neufeldt CJ, Cerikan B and Lu JM:
Structures and distributions of SARS-CoV-2 spike proteins on intact
virions. Nature. 588:498–502. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Mehta P, McAuley DF, Brown M, Sanchez E,
Tattersall RS and Manson JJ; HLH Across Speciality Collaboration
UK, : COVID-19: Consider cytokine storm syndromes and
immunosuppression. Lancet. 395:1033–1034. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Thacker VV, Sharma K, Dhar N, Mancini GF,
Sordet-Dessimoz J and McKinney JD: Rapid endotheliitis and vascular
damage characterize SARS-CoV-2 infection in a human lung-on-chip
model. EMBO Rep. 22:e527442021. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Batah SS and Fabro AT: Pulmonary pathology
of ARDS in COVID-19: A pathological review for clinicians. Respir
Med. 176:1062392021. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Bellani G, Laffey JG, Pham T, Fan E,
Brochard L, Esteban A, Gattinoni L, van Haren F, Larsson A, McAuley
DF, et al: Epidemiology, patterns of care, and mortality for
patients with acute respiratory distress syndrome in intensive care
units in 50 countries. JAMA. 315:788–800. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Harvey WT, Carabelli AM, Jackson B, Gupta
RK, Thomson EC, Harrison EM, Ludden C, Reeve R, Rambaut A; COVID-19
Genomics UK (COG-UK) Consortium, ; et al: SARS-CoV-2 variants,
spike mutations and immune escape. Nat Rev Microbiol. 19:409–424.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Bian L, Gao Q, Gao F, Wang Q, He Q, Wu X,
Mao Q, Xu M and Liang Z: Impact of the delta variant on vaccine
efficacy and response strategies. Expert Rev Vaccines.
20:1201–1209. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Sternberg A and Naujokat C: Structural
features of coronavirus SARS-CoV-2 spike protein: Targets for
vaccination. Life Sci. 257:1180562020. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Hoffmann M, Krüger N, Schulz S, Cossmann
A, Rocha C, Kempf A, Nehlmeier I, Graichen L, Moldenhauer AS,
Winkler MS, et al: The omicron variant is highly resistant against
antibody-mediated neutralization: Implications for control of the
COVID-19 pandemic. Cell. 185:447–456.e11. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ahn DG, Shin HJ, Kim MH, Lee S, Kim HS,
Myoung J, Kim BT and Kim SJ: Current status of epidemiology,
diagnosis, therapeutics, and vaccines for novel coronavirus disease
2019 (COVID-19). J Microbiol Biotechnol. 30:313–324. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Shiehzadegan S, Alaghemand N, Fox M and
Venketaraman V: Analysis of the delta variant B.1.617.2 COVID-19.
Clin Pract. 11:778–784. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kannan SR, Spratt AN, Cohen AR, Naqvi SH,
Chand HS, Quinn TP, Lorson CL, Byrareddy SN and Singh K:
Evolutionary analysis of the delta and delta plus variants of the
SARS-CoV-2 viruses. J Autoimmun. 124:1027152021. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Chen J, Wang R, Gilby NB and Wei GW:
Omicron variant (B.1.1.529): Infectivity, vaccine breakthrough, and
antibody resistance. J Chem Inf Model. 62:412–422. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wang J, Yin XG, Wen Y, Lu J, Zhang RY,
Zhou SH, Liao CM, Wei HW and Guo J: MPLA-adjuvanted liposomes
encapsulating S-trimer or RBD or S1, but not S-ECD, elicit robust
neutralization against SARS-CoV-2 and variants of concern. J Med
Chem. 65:3563–3574. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Meo SA, Meo AS, Al-Jassir FF and Klonoff
DC: Omicron SARS-CoV-2 new variant: Global prevalence and
biological and clinical characteristics. Eur Rev Med Pharmacol Sci.
25:8012–8018. 2021.PubMed/NCBI
|
|
23
|
Chen N, Zhou M, Dong X, Qu J, Gong F, Han
Y, Qiu Y, Wang J, Liu Y, Wei Y, et al: Epidemiological and clinical
characteristics of 99 cases of 2019 novel coronavirus pneumonia in
Wuhan, China: A descriptive study. Lancet. 395:507–513. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Al-Shamsi HO, Alhazzani W, Alhuraiji A,
Coomes EA, Chemaly RF, Almuhanna M, Wolff RA, Ibrahim NK, Chua MLK,
Hotte SJ, et al: A practical approach to the management of cancer
patients during the novel coronavirus disease 2019 (COVID-19)
pandemic: An international collaborative group. Oncologist.
25:e936–e945. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Grasselli G, Zangrillo A, Zanella A,
Antonelli M, Cabrini L, Castelli A, Cereda D, Coluccello A, Foti G,
Fumagalli R, et al: Baseline characteristics and outcomes of 1591
patients infected with SARS-CoV-2 admitted to ICUs of the lombardy
region, Italy. JAMA. 323:1574–1581. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Halpin DMG, Faner R, Sibila O, Badia JR
and Agusti A: Do chronic respiratory diseases or their treatment
affect the risk of SARS-CoV-2 infection? Lancet Respir Med.
8:436–438. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Luo C, Yao L, Zhang L, Yao M, Chen X, Wang
Q and Shen H: Possible transmission of severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) in a public bath center in
Huai'an, Jiangsu Province, China. JAMA Netw Open. 3:e2045832020.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Chan JF, Yuan S, Kok KH, To KK, Chu H,
Yang J, Xing F, Liu J, Yip CC, Poon RW, et al: A familial cluster
of pneumonia associated with the 2019 novel coronavirus indicating
person-to-person transmission: A study of a family cluster. Lancet.
395:514–523. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Kampf G, Todt D, Pfaender S and Steinmann
E: Persistence of coronaviruses on inanimate surfaces and their
inactivation with biocidal agents. J Hosp Infect. 104:246–251.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Atzrodt CL, Maknojia I, McCarthy RDP,
Oldfield TM, Po J, Ta KTL, Stepp HE and Clements TP: A guide to
COVID-19: A global pandemic caused by the novel coronavirus
SARS-CoV-2. FEBS J. 287:3633–3650. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Jayaweera M, Perera H, Gunawardana B and
Manatunge J: Transmission of COVID-19 virus by droplets and
aerosols: A critical review on the unresolved dichotomy. Environ
Res. 188:1098192020. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Morawska L and Cao J: Airborne
transmission of SARS-CoV-2: The world should face the reality.
Environ Int. 139:1057302020. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Gao Z, Xu Y, Sun C, Wang X, Guo Y, Qiu S
and Ma K: A systematic review of asymptomatic infections with
COVID-19. J Microbiol Immunol Infect. 54:12–16. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Pereira LJ, Pereira CV, Murata RM, Pardi V
and Pereira-Dourado SM: Biological and social aspects of
coronavirus disease 2019 (COVID-19) related to oral health. Braz
Oral Res. 34:e0412020. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Jackson CB, Farzan M, Chen B and Choe H:
Mechanisms of SARS-CoV-2 entry into cells. Nat Rev Mol Cell Biol.
23:3–20. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Meyerowitz EA, Richterman A, Gandhi RT and
Sax PE: Transmission of SARS-CoV-2: A review of viral, host, and
environmental factors. Ann Intern Med. 174:69–79. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Wild PS, Dimmeler S and Eschenhagen T: An
epidemiological study exploring a possible impact of treatment with
ACE inhibitors or angiotensin receptor blockers on ACE2 plasma
concentrations. J Mol Cell Cardiol. 141:108–109. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Bai Y, Yao L, Wei T, Tian F, Jin DY, Chen
L and Wang M: Presumed asymptomatic carrier transmission of
COVID-19. JAMA. 323:1406–1407. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Soetikno R, Teoh AYB, Kaltenbach T, Lau
JYW, Asokkumar R, Cabral-Prodigalidad P and Shergill A:
Considerations in performing endoscopy during the COVID-19
pandemic. Gastrointest Endosc. 92:176–183. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Ludwig S and Zarbock A: Coronaviruses and
SARS-CoV-2: A brief overview. Anesth Analg. 131:93–96. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Zhang J, Yang S, Xu Y, Qin X, Liu J, Guo
J, Tian S, Wang S, Liao K, Zhang Y, et al: Epidemiological and
clinical characteristics of imported cases of COVID-19: A
multicenter study. BMC Infect Dis. 21:4062021. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Giacomelli A, Pezzati L, Conti F,
Bernacchia D, Siano M, Oreni L, Rusconi S, Gervasoni C, Ridolfo AL,
Rizzardini G, et al: Self-reported olfactory and taste disorders in
patients with severe acute respiratory coronavirus 2 infection: A
cross-sectional study. Clin Infect Dis. 71:889–890. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Cele S, Jackson L, Khoury DS, Khan K,
Moyo-Gwete T, Tegally H, San JE, Cromer D, Scheepers C, Amoako DG,
et al: Omicron extensively but incompletely escapes Pfizer BNT162b2
neutralization. Nature. 602:654–656. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J,
Wang B, Xiang H, Cheng Z, Xiong Y, et al: Clinical characteristics
of 138 hospitalized patients with 2019 novel coronavirus-infected
pneumonia in Wuhan, China. JAMA. 323:1061–1069. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Wong RSY: The SARS-CoV-2 outbreak: An
epidemiological and clinical perspective. SN Compr Clin Med.
2:1983–1991. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Mohamadian M, Chiti H, Shoghli A, Biglari
S, Parsamanesh N and Esmaeilzadeh A: COVID-19: Virology, biology
and novel laboratory diagnosis. J Gene Med. 23:e33032021.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Chen T, Wu D, Chen H, Yan W, Yang D, Chen
G, Ma K, Xu D, Yu H, Wang H, et al: Clinical characteristics of 113
deceased patients with coronavirus disease 2019: Retrospective
study. BMJ. 368:m10912020. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Fang X, Zhao M, Li S, Yang L and Wu B:
Changes of CT findings in a 2019 novel coronavirus (2019-nCoV)
pneumonia patient. QJM. 113:271–272. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
George PM, Wells AU and Jenkins RG:
Pulmonary fibrosis and COVID-19: The potential role for
antifibrotic therapy. Lancet Respir Med. 8:807–815. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Ma X, Liang M, Ding M, Liu W, Ma H, Zhou X
and Ren H: Extracorporeal membrane oxygenation (ECMO) in critically
Ill patients with coronavirus disease 2019 (COVID-19) pneumonia and
acute respiratory distress syndrome (ARDS). Med Sci Monit.
26:e9253642020. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Baruah V and Bose S:
Immunoinformatics-aided identification of T cell and B cell
epitopes in the surface glycoprotein of 2019-nCoV. J Med Virol.
92:495–500. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Sieker JT, Horowitz C, Hu CK,
Lacombe-Daphnis M, Chirokas B, Pina C, Heger NE, Rabson AR, Zhou M,
Bogen SA and Horowitz GL: Analytic sensitivity of 3 nucleic acid
detection assays in diagnosis of SARS-CoV-2 infection. J Appl Lab
Med. 6:421–428. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Huang C, Huang L, Wang Y, Li X, Ren L, Gu
X, Kang L, Guo L, Liu M, Zhou X, et al: 6-month consequences of
COVID-19 in patients discharged from hospital: A cohort study.
Lancet. 397:220–232. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Chams N, Chams S, Badran R, Shams A, Araji
A, Raad M, Mukhopadhyay S, Stroberg E, Duval EJ, Barton LM and Hajj
Hussein I: COVID-19: A multidisciplinary review. Front Public
Health. 8:3832020. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Stang A, Robers J, Schonert B, Jöckel KH,
Spelsberg A, Keil U and Cullen P: The performance of the SARS-CoV-2
RT-PCR test as a tool for detecting SARS-CoV-2 infection in the
population. J Infect. 83:237–279. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Islam KU and Iqbal J: An update on
molecular diagnostics for COVID-19. Front Cell Infect Microbiol.
10:5606162020. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Kucirka LM, Lauer SA, Laeyendecker O, Boon
D and Lessler J: Variation in false-negative rate of reverse
transcriptase polymerase chain reaction-based SARS-CoV-2 tests by
time since exposure. Ann Intern Med. 173:262–267. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Harper H, Burridge A, Winfield M, Finn A,
Davidson A, Matthews D, Hutchings S, Vipond B, Jain N; COVID-19
Genomics UK (COG-UK) Consortium, ; et al: Detecting SARS-CoV-2
variants with SNP genotyping. PLoS One. 16:e02431852021. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Stelzer-Braid S, Walker GJ, Aggarwal A,
Isaacs SR, Yeang M, Naing Z, Ospina Stella A, Turville SG and
Rawlinson WD: Virus isolation of severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) for diagnostic and research purposes.
Pathology. 52:760–763. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Kleiboeker S, Cowden S, Grantham J, Nutt
J, Tyler A, Berg A and Altrich M: SARS-CoV-2 viral load assessment
in respiratory samples. J Clin Virol. 129:1044392020. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Zhang W, Du RH, Li B, Zheng XS, Yang XL,
Hu B, Wang YY, Xiao GF, Yan B, Shi ZL and Zhou P: Molecular and
serological investigation of 2019-nCoV infected patients:
Implication of multiple shedding routes. Emerg Microbes Infect.
9:386–389. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Shen M, Zhou Y, Ye J, Abdullah Al-Maskri
AA, Kang Y, Zeng S and Cai S: Recent advances and perspectives of
nucleic acid detection for coronavirus. J Pharm Anal. 10:97–101.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Bustin SA and Mueller R: Real-time reverse
transcription PCR (qRT-PCR) and its potential use in clinical
diagnosis. Clin Sci (Lond). 109:365–379. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
To KK, Tsang OT, Leung WS, Tam AR, Wu TC,
Lung DC, Yip CC, Cai JP, Chan JM, Chik TS, et al: Temporal profiles
of viral load in posterior oropharyngeal saliva samples and serum
antibody responses during infection by SARS-CoV-2: An observational
cohort study. Lancet Infect Dis. 20:565–574. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Thomas E, Delabat S, Carattini YL and
Andrews DM: SARS-CoV-2 and variant diagnostic testing approaches in
the United States. Viruses. 13:24922021. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Safiabadi Tali SH, LeBlanc JJ, Sadiq Z,
Oyewunmi OD, Camargo C, Nikpour B, Armanfard N, Sagan SM and
Jahanshahi-Anbuhi S: Tools and techniques for severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2)/COVID-19 detection.
Clin Microbiol Rev. 34:e00228–20. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Augustine R, Hasan A, Das S, Ahmed R, Mori
Y, Notomi T, Kevadiya BD and Thakor AS: Loop-mediated isothermal
amplification (LAMP): A rapid, sensitive, specific, and
cost-effective point-of-care test for coronaviruses in the context
of COVID-19 pandemic. Biology (Basel). 9:1822020.PubMed/NCBI
|
|
68
|
Chau CH, Strope JD and Figg WD: COVID-19
clinical diagnostics and testing technology. Pharmacotherapy.
40:857–868. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Alcoba-Florez J, Gil-Campesino H, Artola
DG, González-Montelongo R, Valenzuela-Fernández A, Ciuffreda L and
Flores C: Sensitivity of different RT-qPCR solutions for SARS-CoV-2
detection. Int J Infect Dis. 99:190–192. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Giuliani C: The flavonoid quercetin
induces AP-1 activation in FRTL-5 thyroid cells. Antioxidants
(Basel). 8:1122019. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Ye Z, Zhang Y, Wang Y, Huang Z and Song B:
Chest CT manifestations of new coronavirus disease 2019 (COVID-19):
A pictorial review. Eur Radiol. 30:4381–4389. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Kanne JP: Chest CT findings in 2019 novel
coronavirus (2019-nCoV) infections from Wuhan, China: Key points
for the radiologist. Radiology. 295:16–17. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Nivet H, Crombé A, Schuster P, Ayoub T,
Pourriol L, Favard N, Chazot A, Alonzo-Lacroix F, Youssof E, Ben
Cheikh A, et al: The accuracy of teleradiologists in diagnosing
COVID-19 based on a French multicentric emergency cohort. Eur
Radiol. 31:2833–2844. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Ghose A, Roy S, Vasdev N, Olsburgh J and
Dasgupta P: The emerging role of artificial intelligence in the
fight against COVID-19. Eur Urol. 78:775–776. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Ozsahin I, Sekeroglu B, Musa MS, Mustapha
MT and Uzun Ozsahin D: Review on diagnosis of COVID-19 from chest
CT images using artificial intelligence. Comput Math Methods Med.
2020:97565182020. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Shi F, Wang J, Shi J, Wu Z, Wang Q, Tang
Z, He K, Shi Y and Shen D: Review of artificial intelligence
techniques in imaging data acquisition, segmentation, and diagnosis
for COVID-19. IEEE Rev Biomed Eng. 14:4–15. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Bouchareb Y, Moradi Khaniabadi P, Al Kindi
F, Al Dhuhli H, Shiri I, Zaidi H and Rahmim A: Artificial
intelligence-driven assessment of radiological images for COVID-19.
Comput Biol Med. 136:1046652021. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Vaishya R, Javaid M, Khan IH and Haleem A:
Artificial intelligence (AI) applications for COVID-19 pandemic.
Diabetes Metab Syndr. 14:337–339. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Dror AA, Eisenbach N, Taiber S, Morozov
NG, Mizrachi M, Zigron A, Srouji S and Sela E: Vaccine hesitancy:
The next challenge in the fight against COVID-19. Eur J Epidemiol.
35:775–779. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Mouffak S, Shubbar Q, Saleh E and El-Awady
R: Recent advances in management of COVID-19: A review. Biomed
Pharmacother. 143:1121072021. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Gavriatopoulou M, Ntanasis-Stathopoulos I,
Korompoki E, Fotiou D, Migkou M, Tzanninis IG, Psaltopoulou T,
Kastritis E, Terpos E and Dimopoulos MA: Emerging treatment
strategies for COVID-19 infection. Clin Exp Med. 21:167–179. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Richtsmeier WJ: Interferon-present and
future prospects. Crit Rev Clin Lab Sci. 20:57–93. 1984. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Lee JS and Shin EC: The type I interferon
response in COVID-19: Implications for treatment. Nat Rev Immunol.
20:585–586. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Hadjadj J, Yatim N, Barnabei L, Corneau A,
Boussier J, Smith N, Péré H, Charbit B, Bondet V, Chenevier-Gobeaux
C, et al: Impaired type I interferon activity and inflammatory
responses in severe COVID-19 patients. Science. 369:718–724. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Monk PD, Marsden RJ, Tear VJ, Brookes J,
Batten TN, Mankowski M, Gabbay FJ, Davies DE, Holgate ST, Ho LP, et
al: Safety and efficacy of inhaled nebulised interferon beta-1a
(SNG001) for treatment of SARS-CoV-2 infection: A randomised,
double-blind, placebo-controlled, phase 2 trial. Lancet Respir Med.
9:196–206. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Rahmani H, Davoudi-Monfared E, Nourian A,
Khalili H, Hajizadeh N, Jalalabadi NZ, Fazeli MR, Ghazaeian M and
Yekaninejad MS: Interferon β-1b in treatment of severe COVID-19: A
randomized clinical trial. Int Immunopharmacol. 88:1069032020.
View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Joseph BA, Dibas M, Evanson KW, Paranjape
G, Vegivinti CTR, Selvan PT, Saravu K, Gupta N, Pulakurthi YS,
Keesari PR, et al: Efficacy and safety of lopinavir/ritonavir in
the treatment of COVID-19: A systematic review. Expert Rev Anti
Infect Ther. 19:679–687. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Wu Y, Ma L, Zhuang Z, Cai S, Zhao Z, Zhou
L, Zhang J, Wang PH, Zhao J and Cui J: Main protease of SARS-CoV-2
serves as a bifunctional molecule in restricting type I interferon
antiviral signaling. Signal Transduct Target Ther. 5:2212020.
View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Cao B, Wang Y, Wen D, Liu W, Wang J, Fan
G, Ruan L, Song B, Cai Y, Wei M, et al: A trial of
lopinavir-ritonavir in adults hospitalized with severe Covid-19. N
Engl J Med. 382:1787–1799. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Hu Y, Ma C, Szeto T, Hurst B, Tarbet B and
Wang J: Boceprevir, calpain inhibitors II and XII, and GC-376 have
broad-spectrum antiviral activity against coronaviruses. ACS Infect
Dis. 7:586–597. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Boras B, Jones RM, Anson BJ, Arenson D,
Aschenbrenner L, Bakowski MA, Beutler N, Binder J, Chen E, Eng H,
et al: Preclinical characterization of an intravenous coronavirus
3CL protease inhibitor for the potential treatment of COVID19. Nat
Commun. 12:60552021. View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Wen W, Chen C, Tang J, Wang C, Zhou M,
Cheng Y, Zhou X, Wu Q, Zhang X, Feng Z, et al: Efficacy and safety
of three new oral antiviral treatment (molnupiravir, fluvoxamine
and Paxlovid) for COVID-19: A meta-analysis. Ann Med. 54:516–523.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Colson P, Rolain JM and Raoult D:
Chloroquine for the 2019 novel coronavirus SARS-CoV-2. Int J
Antimicrob Agents. 55:1059232020. View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Cuadrado-Lavín A, Olmos JM, Cifrian JM,
Gimenez T, Gandarillas MA, García-Saiz M, Rebollo MH,
Martínez-Taboada V, López-Hoyos M, Fariñas MC and Crespo J:
Controlled, double-blind, randomized trial to assess the efficacy
and safety of hydroxychloroquine chemoprophylaxis in SARS CoV2
infection in healthcare personnel in the hospital setting: A
structured summary of a study protocol for a randomised controlled
trial. Trials. 21:4722020. View Article : Google Scholar : PubMed/NCBI
|
|
95
|
RECOVERY Collaborative Group, . Horby P,
Mafham M, Linsell L, Bell JL, Staplin N, Emberson JR, Wiselka M,
Ustianowski A, Elmahi E, et al: Effect of hydroxychloroquine in
hospitalized patients with Covid-19. N Engl J Med. 383:2030–2040.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Gautret P, Lagier JC, Parola P, Hoang VT,
Meddeb L, Mailhe M, Doudier B, Courjon J, Giordanengo V, Vieira VE,
et al: Hydroxychloroquine and azithromycin as a treatment of
COVID-19: Results of an open-label non-randomized clinical trial.
Int J Antimicrob Agents. 56:1059492020. View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Wang X, Cao R, Zhang H, Liu J, Xu M, Hu H,
Li Y, Zhao L, Li W, Sun X, et al: The anti-influenza virus drug,
arbidol is an efficient inhibitor of SARS-CoV-2 in vitro. Cell
Discov. 6:282020. View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Li H, Liu R, Zhang R, Zhang S, Wei Y,
Zhang L, Zhou H and Yang C: Protective effect of arbidol against
pulmonary fibrosis and sepsis in mice. Front Pharmacol.
11:6070752020. View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Zhu Z, Lu Z, Xu T, Chen C, Yang G, Zha T,
Lu J and Xue Y: Arbidol monotherapy is superior to
lopinavir/ritonavir in treating COVID-19. J Infect. 81:e21–e23.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Song Y, Zhang M, Yin L, Wang K, Zhou Y,
Zhou M and Lu Y: COVID-19 treatment: close to a cure? A rapid
review of pharmacotherapies for the novel coronavirus (SARS-CoV-2).
Int J Antimicrob Agents. 56:1060802020. View Article : Google Scholar : PubMed/NCBI
|
|
101
|
Wang B, Timilsena YP, Blanch E and
Adhikari B: Lactoferrin: Structure, function, denaturation and
digestion. Crit Rev Food Sci Nutr. 59:580–596. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
102
|
Hu Y, Meng X, Zhang F, Xiang Y and Wang J:
The in vitro antiviral activity of lactoferrin against common human
coronaviruses and SARS-CoV-2 is mediated by targeting the heparan
sulfate co-receptor. Emerg Microbes Infect. 10:317–330. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
103
|
Salaris C, Scarpa M, Elli M, Bertolini A,
Guglielmetti S, Pregliasco F, Blandizzi C, Brun P and Castagliuolo
I: Protective effects of lactoferrin against SARS-CoV-2 infection
in vitro. Nutrients. 13:3282021. View Article : Google Scholar : PubMed/NCBI
|
|
104
|
Hoffmann M, Kleine-Weber H, Schroeder S,
Krüger N, Herrler T, Erichsen S, Schiergens TS, Herrler G, Wu NH,
Nitsche A, et al: SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2
and is blocked by a clinically proven protease inhibitor. Cell.
181:271–280.e8. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
105
|
Tian L, Qiang T, Liang C, Ren X, Jia M,
Zhang J, Li J, Wan M, YuWen X, Li H, et al: RNA-dependent RNA
polymerase (RdRp) inhibitors: The current landscape and repurposing
for the COVID-19 pandemic. Eur J Med Chem. 213:1132012021.
View Article : Google Scholar : PubMed/NCBI
|
|
106
|
Cao YC, Deng QX and Dai SX: Remdesivir for
severe acute respiratory syndrome coronavirus 2 causing COVID-19:
An evaluation of the evidence. Travel Med Infect Dis.
35:1016472020. View Article : Google Scholar : PubMed/NCBI
|
|
107
|
McDonald S, Turner S, Page MJ and Turner
T: Most published systematic reviews of remdesivir for COVID-19
were redundant and lacked currency. J Clin Epidemiol. 146:22–31.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
108
|
Jayk Bernal A, Gomes da Silva MM,
Musungaie DB, Kovalchuk E, Gonzalez A, Delos Reyes V, Martín-Quirós
A, Caraco Y, Williams-Diaz A, Brown ML, et al: Molnupiravir for
oral treatment of Covid-19 in nonhospitalized patients. N Engl J
Med. 386:509–520. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
109
|
Good SS, Westover J, Jung KH, Zhou XJ,
Moussa A, La Colla P, Collu G, Canard B and Sommadossi JP: AT-527,
a double prodrug of a guanosine nucleotide analog, is a potent
inhibitor of SARS-CoV-2 in vitro and a promising oral antiviral for
treatment of COVID-19. Antimicrob Agents Chemother. 65:e02479–20.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
110
|
Martinez MA: Plitidepsin: A repurposed
drug for the treatment of COVID-19. Antimicrob Agents Chemother.
65:e00200–21. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
111
|
White KM, Rosales R, Yildiz S, Kehrer T,
Miorin L, Moreno E, Jangra S, Uccellini MB, Rathnasinghe R,
Coughlan L, et al: Plitidepsin has potent preclinical efficacy
against SARS-CoV-2 by targeting the host protein eEF1A. Science.
371:926–931. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
112
|
Rodon J, Muñoz-Basagoiti J, Perez-Zsolt D,
Noguera-Julian M, Paredes R, Mateu L, Quiñones C, Perez C, Erkizia
I, Blanco I, et al: Identification of plitidepsin as potent
inhibitor of SARS-CoV-2-induced cytopathic effect after a drug
repurposing screen. Front Pharmacol. 12:6466762021. View Article : Google Scholar : PubMed/NCBI
|
|
113
|
Soto-Matos A, Szyldergemajn S, Extremera
S, Miguel-Lillo B, Alfaro V, Coronado C, Lardelli P, Roy E, Corrado
CS and Kahatt C: Plitidepsin has a safe cardiac profile: A
comprehensive analysis. Mar Drugs. 9:1007–1023. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
114
|
Lenze EJ, Mattar C, Zorumski CF, Stevens
A, Schweiger J, Nicol GE, Miller JP, Yang L, Yingling M, Avidan MS
and Reiersen AM: Fluvoxamine vs placebo and clinical deterioration
in outpatients with symptomatic COVID-19: A randomized clinical
trial. JAMA. 324:2292–2300. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
115
|
Bartoszko JJ, Siemieniuk RAC, Kum E, Qasim
A, Zeraatkar D, Ge L, Han MA, Sadeghirad B, Agarwal A, Agoritsas T,
et al: Prophylaxis against covid-19: Living systematic review and
network meta-analysis. BMJ. 373:n9492021. View Article : Google Scholar : PubMed/NCBI
|
|
116
|
Wang X, Guo X, Xin Q, Pan Y, Hu Y, Li J,
Chu Y, Feng Y and Wang Q: Neutralizing antibody responses to severe
acute respiratory syndrome coronavirus 2 in coronavirus disease
2019 inpatients and convalescent patients. Clin Infect Dis.
71:2688–2694. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
117
|
Libster R, Pérez Marc G, Wappner D,
Coviello S, Bianchi A, Braem V, Esteban I, Caballero MT, Wood C,
Berrueta M, et al: Early high-titer plasma therapy to prevent
severe Covid-19 in older adults. N Engl J Med. 384:610–618. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
118
|
Abolghasemi H, Eshghi P, Cheraghali AM,
Imani Fooladi AA, Bolouki Moghaddam F, Imanizadeh S, Moeini Maleki
M, Ranjkesh M, Rezapour M, Bahramifar A, et al: Clinical efficacy
of convalescent plasma for treatment of COVID-19 infections:
Results of a multicenter clinical study. Transfus Apher Sci.
59:1028752020. View Article : Google Scholar : PubMed/NCBI
|
|
119
|
Shen C, Wang Z, Zhao F, Yang Y, Li J, Yuan
J, Wang F, Li D, Yang M, Xing L, et al: Treatment of 5 critically
Ill patients with COVID-19 with convalescent plasma. JAMA.
323:1582–1589. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
120
|
Joyner MJ, Bruno KA, Klassen SA, Kunze KL,
Johnson PW, Lesser ER, Wiggins CC, Senefeld JW, Klompas AM, Hodge
DO, et al: Safety update: COVID-19 convalescent plasma in 20,000
hospitalized patients. Mayo Clin Proc. 95:1888–1897. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
121
|
Cao W, Liu X, Bai T, Fan H, Hong K, Song
H, Han Y, Lin L, Ruan L and Li T: High-dose intravenous
immunoglobulin as a therapeutic option for deteriorating patients
with coronavirus disease 2019. Open Forum Infect Dis.
7:ofaa1022020. View Article : Google Scholar : PubMed/NCBI
|
|
122
|
Cao W, Liu X, Hong K, Ma Z, Zhang Y, Lin
L, Han Y, Xiong Y, Liu Z, Ruan L and Li T: High-dose intravenous
immunoglobulin in severe coronavirus disease 2019: A multicenter
retrospective study in China. Front Immunol. 12:6278442021.
View Article : Google Scholar : PubMed/NCBI
|
|
123
|
Scialo F, Daniele A, Amato F, Pastore L,
Matera MG, Cazzola M, Castaldo G and Bianco A: ACE2: The major cell
entry receptor for SARS-CoV-2. Lung. 198:867–877. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
124
|
Shi R, Shan C, Duan X, Chen Z, Liu P, Song
J, Song T, Bi X, Han C, Wu L, et al: A human neutralizing antibody
targets the receptor-binding site of SARS-CoV-2. Nature.
584:120–124. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
125
|
Shepard HM, Phillips GL, D Thanos C and
Feldmann M: Developments in therapy with monoclonal antibodies and
related proteins. Clin Med (Lond). 17:220–232. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
126
|
Jackson LA, Anderson EJ, Rouphael NG,
Roberts PC, Makhene M, Coler RN, McCullough MP, Chappell JD,
Denison MR, Stevens LJ, et al: An mRNA vaccine against
SARS-CoV-2-preliminary report. N Engl J Med. 383:1920–1931. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
127
|
Khan FA, Stewart I, Fabbri L, Moss S,
Robinson K, Smyth AR and Jenkins G: Systematic review and
meta-analysis of anakinra, sarilumab, siltuximab and tocilizumab
for COVID-19. Thorax. 76:907–919. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
128
|
Gupta S, Wang W, Hayek SS, Chan L, Mathews
KS, Melamed ML, Brenner SK, Leonberg-Yoo A, Schenck EJ, Radbel J,
et al: Association between early treatment with tocilizumab and
mortality among critically Ill patients with COVID-19. JAMA Intern
Med. 181:41–51. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
129
|
Weinreich DM, Sivapalasingam S, Norton T,
Ali S, Gao H, Bhore R, Xiao J, Hooper AT, Hamilton JD, Musser BJ,
et al: REGEN-COV antibody combination and outcomes in outpatients
with Covid-19. N Engl J Med. 385:e812021. View Article : Google Scholar : PubMed/NCBI
|
|
130
|
O'Brien MP, Forleo-Neto E, Musser BJ, Isa
F, Chan KC, Sarkar N, Bar KJ, Barnabas RV, Barouch DH, Cohen MS, et
al: Subcutaneous REGEN-COV antibody combination to prevent
Covid-19. N Engl J Med. 385:1184–1195. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
131
|
Ryu DK, Kang B, Noh H, Woo SJ, Lee MH,
Nuijten PM, Kim JI, Seo JM, Kim C, Kim M, et al: The in vitro and
in vivo efficacy of CT-P59 against gamma, delta and its associated
variants of SARS-CoV-2. Biochem Biophys Res Commun. 578:91–96.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
132
|
Lescure FX, Honda H, Fowler RA, Lazar JS,
Shi G, Wung P, Patel N and Hagino O; Sarilumab COVID-19 Global
Study Group, : Sarilumab in patients admitted to hospital with
severe or critical COVID-19: A randomised, double-blind,
placebo-controlled, phase 3 trial. Lancet Respir Med. 9:522–532.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
133
|
Pang J, Xu F, Aondio G, Li Y, Fumagalli A,
Lu M, Valmadre G, Wei J, Bian Y, Canesi M, et al: Efficacy and
tolerability of bevacizumab in patients with severe Covid-19. Nat
Commun. 12:8142021. View Article : Google Scholar : PubMed/NCBI
|
|
134
|
Tuccori M, Ferraro S, Convertino I,
Cappello E, Valdiserra G, Blandizzi C, Maggi F and Focosi D:
Anti-SARS-CoV-2 neutralizing monoclonal antibodies: Clinical
pipeline. MAbs. 12:18541492020. View Article : Google Scholar : PubMed/NCBI
|
|
135
|
Dejnirattisai W, Huo J, Zhou D, Zahradník
J, Supasa P, Liu C, Duyvesteyn HME, Ginn HM, Mentzer AJ,
Tuekprakhon A, et al: SARS-CoV-2 omicron-B.1.1.529 leads to
widespread escape from neutralizing antibody responses. Cell.
185:467–484.e15. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
136
|
Cao Y, Wang J, Jian F, Xiao T, Song W,
Yisimayi A, Huang W, Li Q, Wang P, An R, et al: Omicron escapes the
majority of existing SARS-CoV-2 neutralizing antibodies. Nature.
602:657–663. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
137
|
Mannar D, Saville JW, Zhu X, Srivastava
SS, Berezuk AM, Tuttle KS, Marquez AC, Sekirov I and Subramaniam S:
SARS-CoV-2 omicron variant: Antibody evasion and cryo-EM structure
of spike protein-ACE2 complex. Science. 375:760–764. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
138
|
Miller NL, Clark T, Raman R and
Sasisekharan R: Insights on the mutational landscape of the
SARS-CoV-2 omicron variant. bioRxiv. doi: 10.1101/2021.12.06.471499
(Preprint).
|
|
139
|
Shah M and Woo HG: Omicron: A heavily
mutated SARS-CoV-2 variant exhibits stronger binding to ACE2 and
potently escapes approved COVID-19 therapeutic antibodies. Front
Immunol. 12:8305272021. View Article : Google Scholar : PubMed/NCBI
|
|
140
|
Chen RE, Winkler ES, Case JB, Aziati ID,
Bricker TL, Joshi A, Darling TL, Ying B, Errico JM, Shrihari S, et
al: In vivo monoclonal antibody efficacy against SARS-CoV-2 variant
strains. Nature. 596:103–108. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
141
|
Kakoulidis I, Ilias I and Koukkou E:
SARS-CoV-2 infection and glucose homeostasis in pregnancy. What
about antenatal corticosteroids? Diabetes Metab Syndr. 14:519–520.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
142
|
Bartoletti M, Marconi L, Scudeller L,
Pancaldi L, Tedeschi S, Giannella M, Rinaldi M, Bussini L,
Valentini I, Ferravante AF, et al: Efficacy of corticosteroid
treatment for hospitalized patients with severe COVID-19: A
multicentre study. Clin Microbiol Infect. 27:105–111. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
143
|
Tang X, Feng YM, Ni JX, Zhang JY, Liu LM,
Hu K, Wu XZ, Zhang JX, Chen JW, Zhang JC, et al: Early use of
corticosteroid may prolong SARS-CoV-2 shedding in non-intensive
care unit patients with COVID-19 pneumonia: A multicenter,
single-blind, randomized control trial. Respiration. 100:116–126.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
144
|
van Paassen J, Vos JS, Hoekstra EM,
Neumann KMI, Boot PC and Arbous SM: Corticosteroid use in COVID-19
patients: A systematic review and meta-analysis on clinical
outcomes. Crit Care. 24:6962020. View Article : Google Scholar : PubMed/NCBI
|
|
145
|
So C, Ro S, Murakami M, Imai R and Jinta
T: High-dose, short-term corticosteroids for ARDS caused by
COVID-19: A case series. Respirol Case Rep. 8:e005962020.
View Article : Google Scholar : PubMed/NCBI
|
|
146
|
Kolilekas L, Loverdos K, Giannakaki S,
Vlassi L, Levounets A, Zervas E and Gaga M: Can steroids reverse
the severe COVID-19 induced ‘cytokine storm’? J Med Virol.
92:2866–2869. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
147
|
Yuan M, Xu X, Xia D, Tao Z, Yin W, Tan W,
Hu Y and Song C: Effects of corticosteroid treatment for non-severe
COVID-19 pneumonia: A propensity score-based analysis. Shock.
54:638–643. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
148
|
Lu X, Chen T, Wang Y, Wang J and Yan F:
Adjuvant corticosteroid therapy for critically ill patients with
COVID-19. Crit Care. 24:2412020. View Article : Google Scholar : PubMed/NCBI
|
|
149
|
Rello J, Belliato M, Dimopoulos MA,
Giamarellos-Bourboulis EJ, Jaksic V, Martin-Loeches I, Mporas I,
Pelosi P, Poulakou G, Pournaras S, et al: Update in COVID-19 in the
intensive care unit from the 2020 HELLENIC Athens International
symposium. Anaesth Crit Care Pain Med. 39:723–730. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
150
|
Lentz S, Roginski MA, Montrief T, Ramzy M,
Gottlieb M and Long B: Initial emergency department mechanical
ventilation strategies for COVID-19 hypoxemic respiratory failure
and ARDS. Am J Emerg Med. 38:2194–2202. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
151
|
Wong DJN, El-Boghdadly K, Owen R,
Johnstone C, Neuman MD, Andruszkiewicz P, Baker PA, Biccard BM,
Bryson GL, Chan MTV, et al: Emergency airway management in patients
with COVID-19: A prospective international multicenter cohort
study. Anesthesiology. 135:292–303. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
152
|
Cook TM, El-Boghdadly K, McGuire B,
McNarry AF, Patel A and Higgs A: Consensus guidelines for managing
the airway in patients with COVID-19: Guidelines from the difficult
airway society, the association of anaesthetists the intensive care
society, the faculty of intensive care medicine and the royal
college of anaesthetists. Anaesthesia. 75:785–799. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
153
|
Llitjos JF, Leclerc M, Chochois C,
Monsallier JM, Ramakers M, Auvray M and Merouani K: High incidence
of venous thromboembolic events in anticoagulated severe COVID-19
patients. J Thromb Haemost. 18:1743–1746. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
154
|
Ronco C, Reis T and Husain-Syed F:
Management of acute kidney injury in patients with COVID-19. Lancet
Respir Med. 8:738–742. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
155
|
Ronco C, Bagshaw SM, Bellomo R, Clark WR,
Husain-Syed F, Kellum JA, Ricci Z, Rimmelé T, Reis T and Ostermann
M: Extracorporeal blood purification and organ support in the
critically Ill patient during COVID-19 Pandemic: expert review and
recommendation. Blood Purif. 50:17–27. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
156
|
Kabeerdoss J, Pilania RK, Karkhele R,
Kumar TS, Danda D and Singh S: Severe COVID-19, multisystem
inflammatory syndrome in children, and Kawasaki disease:
Immunological mechanisms, clinical manifestations and management.
Rheumatol Int. 41:19–32. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
157
|
Megyeri K, Dernovics Á, Al-Luhaibi ZII and
Rosztóczy A: COVID-19-associated diarrhea. World J Gastroenterol.
27:3208–3222. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
158
|
Lu ZH, Yang CL, Yang GG, Pan WX, Tian LG,
Zheng JX, Lv S, Zhang SY, Zheng PY and Zhang SX: Efficacy of the
combination of modern medicine and traditional Chinese medicine in
pulmonary fibrosis arising as a sequelae in convalescent COVID-19
patients: A randomized multicenter trial. Infect Dis Poverty.
10:312021. View Article : Google Scholar : PubMed/NCBI
|
|
159
|
Zhao Z, Li Y, Zhou L, Zhou X, Xie B, Zhang
W and Sun J: Prevention and treatment of COVID-19 using traditional
Chinese medicine: A review. Phytomedicine. 85:1533082021.
View Article : Google Scholar : PubMed/NCBI
|
|
160
|
Ren JL, Zhang AH and Wang XJ: Traditional
Chinese medicine for COVID-19 treatment. Pharmacol Res.
155:1047432020. View Article : Google Scholar : PubMed/NCBI
|
|
161
|
Ni L, Chen L, Huang X, Han C, Xu J, Zhang
H, Luan X, Zhao Y, Xu J, Yuan W and Chen H: Combating COVID-19 with
integrated traditional Chinese and western medicine in China. Acta
Pharm Sin B. 10:1149–1162. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
162
|
Anand U, Jakhmola S, Indari O, Jha HC,
Chen ZS, Tripathi V and Pérez de la Lastra JM: Potential
therapeutic targets and vaccine development for SARS-CoV-2/COVID-19
pandemic management: A review on the recent update. Front Immunol.
12:6585192021. View Article : Google Scholar : PubMed/NCBI
|
|
163
|
Tregoning JS, Flight KE, Higham SL, Wang Z
and Pierce BF: Progress of the COVID-19 vaccine effort: Viruses,
vaccines and variants versus efficacy, effectiveness and escape.
Nat Rev Immunol. 21:626–636. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
164
|
Hou Z, Tong Y, Du F, Lu L, Zhao S, Yu K,
Piatek SJ, Larson HJ and Lin L: Assessing COVID-19 vaccine
hesitancy, confidence, and public engagement: A global social
listening study. J Med Internet Res. 23:e276322021. View Article : Google Scholar : PubMed/NCBI
|
|
165
|
Sharif N, Alzahrani KJ, Ahmed SN and Dey
SK: Efficacy, immunogenicity and safety of COVID-19 vaccines: A
systematic review and meta-analysis. Front Immunol. 12:7141702021.
View Article : Google Scholar : PubMed/NCBI
|
|
166
|
Francis AI, Ghany S, Gilkes T and
Umakanthan S: Review of COVID-19 vaccine subtypes, efficacy and
geographical distributions. Postgrad Med J. 98:389–394. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
167
|
Canedo-Marroquín G, Saavedra F, Andrade
CA, Berrios RV, Rodríguez-Guilarte L, Opazo MC, Riedel CA and
Kalergis AM: SARS-CoV-2: Immune response elicited by infection and
development of vaccines and treatments. Front Immunol.
11:5697602020. View Article : Google Scholar : PubMed/NCBI
|
|
168
|
Rauch S, Roth N, Schwendt K, Fotin-Mleczek
M, Mueller SO and Petsch B: mRNA-based SARS-CoV-2 vaccine candidate
CVnCoV induces high levels of virus-neutralising antibodies and
mediates protection in rodents. NPJ Vaccines. 6:572021. View Article : Google Scholar : PubMed/NCBI
|
|
169
|
Kremsner PG, Ahuad Guerrero RA, Arana-Arri
E, Aroca Martinez GJ, Bonten M, Chandler R, Corral G, De Block EJL,
Ecker L, Gabor JJ, et al: Efficacy and safety of the CVnCoV
SARS-CoV-2 mRNA vaccine candidate in ten countries in Europe and
Latin America (HERALD): A randomised, observer-blinded,
placebo-controlled, phase 2b/3 trial. Lancet Infect Dis.
22:329–340. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
170
|
Pollock KM, Cheeseman HM, Szubert AJ,
Libri V, Boffito M, Owen D, Bern H, O'Hara J, McFarlane LR, Lemm
NM, et al: Safety and immunogenicity of a self-amplifying RNA
vaccine against COVID-19: COVAC1, a phase I, dose-ranging trial.
EClinical Medicine. 44:1012622022. View Article : Google Scholar : PubMed/NCBI
|
|
171
|
Al Kaabi N, Zhang Y, Xia S, Yang Y, Al
Qahtani MM, Abdulrazzaq N, Al Nusair M, Hassany M, Jawad JS,
Abdalla J, et al: Effect of 2 inactivated SARS-CoV-2 vaccines on
symptomatic COVID-19 infection in adults: A randomized clinical
trial. JAMA. 326:35–45. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
172
|
Premikha M, Chiew CJ, Wei WE, Leo YS, Ong
B, Lye DC, Lee VJ and Tan KB: Comparative effectiveness of mRNA and
inactivated whole virus vaccines against COVID-19 infection and
severe disease in Singapore. Clin Infect Dis. Apr 12–2022.(Epub
ahead of print). PubMed/NCBI
|
|
173
|
Zhang Z, Mateus J, Coelho CH, Dan JM,
Moderbacher CR, Gálvez RI, Cortes FH, Grifoni A, Tarke A, Chang J,
et al: Humoral and cellular immune memory to four COVID-19
vaccines. bioRxiv. doi: 10.1101/2022.03.18.484953 (Preprint).
|
|
174
|
Islam N, Sheils NE, Jarvis MS and Cohen K:
Comparative effectiveness over time of the mRNA-1273 (Moderna)
vaccine and the BNT162b2 (Pfizer-BioNTech) vaccine. Nat Commun.
13:23772022. View Article : Google Scholar : PubMed/NCBI
|
|
175
|
Mohamed K, Rzymski P, Islam MS, Makuku R,
Mushtaq A, Khan A, Ivanovska M, Makka SA, Hashem F, Marquez L, et
al: COVID-19 vaccinations: The unknowns, challenges, and hopes. J
Med Virol. 94:1336–1349. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
176
|
Liu Y, Zhang X, Liu J, Xia H, Zou J,
Muruato AE, Periasamy S, Plante JA, Bopp NE, Kurhade C, et al: A
live-attenuated SARS-CoV-2 vaccine candidate with accessory protein
deletions. bioRxiv. 2022.02.14.480460. 2022.
|
|
177
|
Merzon E, Green I, Somekh E, Vinker S,
Golan-Cohen A, Israel A, Gorohovski A, Frenkel-Morgenstern M and
Stein M: The association of previous vaccination with
live-attenuated varicella zoster vaccine and COVID-19 positivity:
An Israeli population-based study. Vaccines (Basel). 10:742022.
View Article : Google Scholar : PubMed/NCBI
|
|
178
|
Richmond P, Hatchuel L, Dong M, Ma B, Hu
B, Smolenov I, Li P, Liang P, Han HH, Liang J and Clemens R: Safety
and immunogenicity of S-Trimer (SCB-2019), a protein subunit
vaccine candidate for COVID-19 in healthy adults: A phase 1,
randomised, double-blind, placebo-controlled trial. Lancet.
397:682–694. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
179
|
Yang S, Li Y, Dai L, Wang J, He P, Li C,
Fang X, Wang C, Zhao X, Huang E, et al: Safety and immunogenicity
of a recombinant tandem-repeat dimeric RBD-based protein subunit
vaccine (ZF2001) against COVID-19 in adults: Two randomised,
double-blind, placebo-controlled, phase 1 and 2 trials. Lancet
Infect Dis. 21:1107–1119. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
180
|
Jin P, Guo X, Chen W, Ma S, Pan H, Dai L,
Du P, Wang L, Jin L, Chen Y, et al: Safety and immunogenicity of
heterologous boost immunization with an adenovirus type-5-vectored
and protein-subunit-based COVID-19 vaccine (Convidecia/ZF2001): A
randomized, observer-blinded, placebo-controlled trial. PLoS Med.
19:e10039532022. View Article : Google Scholar : PubMed/NCBI
|
|
181
|
Kuhn M, Campillos M, Letunic I, Jensen LJ
and Bork P: A side effect resource to capture phenotypic effects of
drugs. Mol Syst Biol. 6:3432010. View Article : Google Scholar : PubMed/NCBI
|
|
182
|
Menni C, Klaser K, May A, Polidori L,
Capdevila J, Louca P, Sudre CH, Nguyen LH, Drew DA, Merino J, et
al: Vaccine side-effects and SARS-CoV-2 infection after vaccination
in users of the COVID symptom study app in the UK: A prospective
observational study. Lancet Infect Dis. 21:939–949. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
183
|
Vetter V, Denizer G, Friedland LR,
Krishnan J and Shapiro M: Understanding modern-day vaccines: What
you need to know. Ann Med. 50:110–120. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
184
|
Akinosoglou K, Tzivaki I and Marangos M:
Covid-19 vaccine and autoimmunity: Awakening the sleeping dragon.
Clin Immunol. 226:1087212021. View Article : Google Scholar : PubMed/NCBI
|
|
185
|
Baden LR, El Sahly HM, Essink B, Kotloff
K, Frey S, Novak R, Diemert D, Spector SA, Rouphael N, Creech CB,
et al: Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N
Engl J Med. 384:403–416. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
186
|
Lipsitch M, Krammer F, Regev-Yochay G,
Lustig Y and Balicer RD: SARS-CoV-2 breakthrough infections in
vaccinated individuals: Measurement, causes and impact. Nat Rev
Immunol. 22:57–65. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
187
|
Dejnirattisai W, Shaw RH, Supasa P, Liu C,
Stuart AS, Pollard AJ, Liu X, Lambe T, Crook D, Stuart DI, et al:
Reduced neutralisation of SARS-CoV-2 omicron B.1.1.529 variant by
post-immunisation serum. Lancet. 399:234–236. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
188
|
Brown CM, Vostok J, Johnson H, Burns M,
Gharpure R, Sami S, Sabo RT, Hall N, Foreman A, Schubert PL, et al:
Outbreak of SARS-CoV-2 infections, including COVID-19 vaccine
breakthrough infections, associated with large public
gatherings-barnstable county, massachusetts, July 2021. MMWR Morb
Mortal Wkly Rep. 70:1059–1062. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
189
|
Tay MZ, Wiehe K and Pollara J:
Antibody-dependent cellular phagocytosis in antiviral immune
responses. Front Immunol. 10:3322019. View Article : Google Scholar : PubMed/NCBI
|
|
190
|
Forni G and Mantovani A; COVID-19
Commission of Accademia Nazionale dei Lincei Rome, : COVID-19
vaccines: Where we stand and challenges ahead. Cell Death Differ.
28:626–639. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
191
|
Bagheri A, Moezzi SMI, Mosaddeghi P,
Nadimi Parashkouhi S, Fazel Hoseini SM, Badakhshan F and
Negahdaripour M: Interferon-inducer antivirals: Potential
candidates to combat COVID-19. Int Immunopharmacol. 91:1072452021.
View Article : Google Scholar : PubMed/NCBI
|
|
192
|
Cáceres CJ, Cardenas-Garcia S, Carnaccini
S, Seibert B, Rajao DS, Wang J and Perez DR: Efficacy of GC-376
against SARS-CoV-2 virus infection in the K18 hACE2 transgenic
mouse model. Sci Rep. 11:96092021. View Article : Google Scholar : PubMed/NCBI
|
|
193
|
Heilmann E, Costacurta F, Geley S,
Mogadashi SA, Volland A, Rupp B, Harris RS and von Laer D: A
VSV-based assay quantifies coronavirus Mpro/3CLpro/Nsp5 main
protease activity and chemical inhibition. Commun Biol. 5:3912022.
View Article : Google Scholar : PubMed/NCBI
|
|
194
|
Mahase E: Covid-19: Covid-19: Pfizer's
paxlovid is 89% effective in patients at risk of serious illness,
company reports. BMJ. 375:n27132021. View Article : Google Scholar : PubMed/NCBI
|
|
195
|
Nojomi M, Yassin Z, Keyvani H, Makiani MJ,
Roham M, Laali A, Dehghan N, Navaei M and Ranjbar M: Effect of
arbidol (Umifenovir) on COVID-19: A randomized controlled trial.
BMC Infect Dis. 20:9542020. View Article : Google Scholar : PubMed/NCBI
|
|
196
|
Chang R, Ng TB and Sun WZ: Lactoferrin as
potential preventative and adjunct treatment for COVID-19. Int J
Antimicrob Agents. 56:1061182020. View Article : Google Scholar : PubMed/NCBI
|
|
197
|
Hoffmann M, Hofmann-Winkler H, Smith JC,
Krüger N, Arora P, Sørensen LK, Søgaard OS, Hasselstrøm JB, Winkler
M, Hempel T, et al: Camostat mesylate inhibits SARS-CoV-2
activation by TMPRSS2-related proteases and its metabolite GBPA
exerts antiviral activity. EBioMedicine. 65:1032552021. View Article : Google Scholar : PubMed/NCBI
|
|
198
|
Wang Y, Zhang D, Du G, Du R, Zhao J, Jin
Y, Fu S, Gao L, Cheng Z, Lu Q, et al: Remdesivir in adults with
severe COVID-19: A randomised, double-blind, placebo-controlled,
multicentre trial. Lancet. 395:1569–1578. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
199
|
Udwadia ZF, Singh P, Barkate H, Patil S,
Rangwala S, Pendse A, Kadam J, Wu W, Caracta CF and Tandon M:
Efficacy and safety of favipiravir, an oral RNA-dependent RNA
polymerase inhibitor, in mild-to-moderate COVID-19: A randomized,
comparative, open-label, multicenter, phase 3 clinical trial. Int J
Infect Diss. 103:62–71. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
200
|
Şimşek-Yavuz S and Komsuoğlu Çelikyurt FI:
An update of anti-viral treatment of COVID-19. Turk J Med Sci.
51:3372–3390. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
201
|
Wood EM, Estcourt LJ and McQuilten ZK: How
should we use convalescent plasma therapies for the management of
COVID-19? Blood. 137:1573–1581. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
202
|
Schmidt F, Weisblum Y, Rutkowska M, Poston
D, DaSilva J, Zhang F, Bednarski E, Cho A, Schaefer-Babajew DJ,
Gaebler C, et al: High genetic barrier to SARS-CoV-2 polyclonal
neutralizing antibody escape. Nature. 600:512–516. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
203
|
Case JB, Chen RE, Cao L, Ying B, Winkler
ES, Johnson M, Goreshnik I, Pham MN, Shrihari S, Kafai NM, et al:
Ultrapotent miniproteins targeting the SARS-CoV-2 receptor-binding
domain protect against infection and disease. Cell Host Microbe.
29:1151–1161.e5. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
204
|
Guo K, Wustoni S, Koklu A, Díaz-Galicia E,
Moser M, Hama A, Alqahtani AA, Ahmad AN, Alhamlan FS, Shuaib M, et
al: Rapid single-molecule detection of COVID-19 and MERS antigens
via nanobody-functionalized organic electrochemical transistors.
Nat Biomed Eng. 5:666–677. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
205
|
Stone JH, Frigault MJ, Serling-Boyd NJ,
Fernandes AD, Harvey L, Foulkes AS, Horick NK, Healy BC, Shah R,
Bensaci AM, et al: Efficacy of tocilizumab in patients hospitalized
with Covid-19. N Engl J Med. 383:2333–2344. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
206
|
Gupta A, Gonzalez-Rojas Y, Juarez E,
Crespo Casal M, Moya J, Falci DR, Sarkis E, Solis J, Zheng H, Scott
N, et al: Early treatment for Covid-19 with SARS-CoV-2 neutralizing
antibody sotrovimab. N Engl J Med. 385:1941–1950. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
207
|
Chen P, Nirula A, Heller B, Gottlieb RL,
Boscia J, Morris J, Huhn G, Cardona J, Mocherla B, Stosor V, et al:
SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with
Covid-19. N Engl J Med. 384:229–237. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
208
|
Kim JY, Jang YR, Hong JH, Jung JG, Park
JH, Streinu-Cercel A, Streinu-Cercel A, Săndulescu O, Lee SJ, Kim
SH, et al: Safety, virologic efficacy, and pharmacokinetics of
CT-P59, a neutralizing monoclonal antibody against SARS-CoV-2 spike
receptor-binding protein: Two randomized, placebo-controlled, phase
I studies in healthy individuals and patients with mild SARS-CoV-2
infection. Clin Ther. 43:1706–1727. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
209
|
Levin MJ, Ustianowski A, De Wit S, Launay
O, Avila M, Templeton A, Yuan Y, Seegobin S, Ellery A, Levinson DJ,
et al: Intramuscular AZD7442 (Tixagevimab-Cilgavimab) for
prevention of Covid-19. N Engl J Med. 386:2188–2200. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
210
|
ACTIV-3/Therapeutics for Inpatients with
COVID-19 (TICO) Study Group, : Efficacy and safety of two
neutralising monoclonal antibody therapies, sotrovimab and BRII-196
plus BRII-198, for adults hospitalised with COVID-19 (TICO): A
randomised controlled trial. Lancet Infect Dis. 22:622–635. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
211
|
Weinreich DM, Sivapalasingam S, Norton T,
Ali S, Gao H, Bhore R, Musser BJ, Soo Y, Rofail D, Im J, et al:
REGN-COV2, a neutralizing antibody cocktail, in outpatients with
Covid-19. N Engl J Med. 384:238–251. 2021. View Article : Google Scholar : PubMed/NCBI
|
